June 2016- Provepharm receives FDA approval to market ProvayBlue™ (methylene blue) Injection

Provepharm, a Provence Technologies Group subsidiary, receives FDA approval to market ProvayBlue™, the first methylene blue injection authorized in the United States.

PDF - 337.7 kb
Press release-Provepharm NDA

Marseille June 20 2016 – Provence Technologies, a life science service and innovation French company, announces that its subsidiary Provepharm, the commercialization company of the products developed and patented by Provence Technologies, has obtained FDA approval to market ProvayBlue™in the United States.